

Peptonic Medical requests extension of corporate reconstruction and provides update on financial performance

**Peptonic Medical AB (publ) ("Peptonic" or the "Company") has today submitted a request to the Uppsala District Court to extend the ongoing corporate reconstruction by three months, until 15 December 2025. The extension is supported by the Company's reconstruction trustee.**

Since the start of the reconstruction, the Company has implemented several important measures to strengthen its financial position. During the period April–August, sales exceeded the forecast published in June, with an increase of approximately SEK 1.4 million in revenue (+16%). The full-year forecast remains in line with previous estimates, and the Company confirms that EBITDA break-even is expected to be reached in November.

The Company's principal shareholder, Maida Vale Capital AB, has provided the Company with bridge financing of up to SEK 3 million. In addition, a prior agreement secures a planned capital raise of SEK 10 million within the framework of the reconstruction. The capital raise is conditional upon the reconstruction plan being approved by the relevant parties, confirmed by the District Court, and gaining legal effect. The Company believes that the planned capital raising, whether carried out as a directed share issue or as a guaranteed rights issue, is sufficient to finance operations and complete the reconstruction.

The Company's full request for extension will be available on the Company's website:  
<https://www.peptonicmedical.se/investerare/foretagsrekonstruktion-2025/>

**For further information, please contact:**

Anna Linton, CEO, Peptonic Medical AB

Email: [anna.linton@peptonicmedical.se](mailto:anna.linton@peptonicmedical.se)

Phone: +46 70-244 92 07

**About Peptonic Medical AB**

PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women's intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic's growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.

The Company is headquartered in Stockholm, Sweden, and operates the subsidiaries, Peptonic Medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.

This disclosure contains information that PEPTONIC Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on September 10, 2025, 19:45 CET.